September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertio..
August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) w..
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) a primit aprobarea regulată a FDA pentru pacienții cu cancer pulmonar fără celule mici (NSCLC) metastatic ale căror tumori sunt pozitive pentru limfom kinaza anaplazică (ALK), după cum a determinat o aplicație FDA.
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) a primit aprobarea regulată a FDA pentru pacienții cu cancer pulmonar fără celule mici (NSCLC) metastatic ale căror tumori sunt pozitive pentru limfom kinaza anaplazică (ALK), după cum a determinat o aplicație FDA.
August 2021: FDA a aprobat cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) pentru tratamentul de primă linie al pacienților cu cancer pulmonar fără celule mici (NSCLC) avansat (avansat local care nu sunt candidați pentru intervenție chirurgicală..
20 august 2021: Recent, în mai 2021, Lumakras (sotorasib) a fost aprobat de Administrația SUA pentru Alimente și Medicamente ca primul tratament pentru pacienții adulți cu cancer pulmonar cu celule mici, care au suferit cel puțin un sistem anterior ..
July 7th 2021 : Tobacco smoking is the leading cause of lung cancer, accounting for over 80% of all fatalities from the disease. People who do not smoke, however, are also susceptible to lung cancer. According to a new study, arou..
What to do about drug resistance of non-small cell lung cancer targeted drugs, you want to know hereLung cancer is the cancer with the highest morbidity and mortality in China. About 1.6 million people die of this disease each yea..
Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most..
Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of the American Society of Oncolo..